Ann: Phase IIb Dog Trial Achieves Interim Clinical Endpoints, page-121

Morning Dryasachip

If you go to the announcements of 2017 you will see 3 ASX announcements surrounding Patents granted to PAA for the use of MPL,,,

PharmAust secures broad patent in US for non-cancer applications of Monepantel
https://stocknessmonster.com/announcements/paa.asx-6A860783/

PharmAust secures broad European patent for non-cancer applications
https://stocknessmonster.com/announcements/paa.asx-6A850465/

PharmAust secures core Europe patent
https://stocknessmonster.com/announcements/paa.asx-6A823472/

PharmAust secures broad patent coverage for non-cancer applications
https://stocknessmonster.com/announcements/paa.asx-6A821157/

PharmAust secures core patent in Japan
https://stocknessmonster.com/announcements/paa.asx-6A823169/

PharmAust and Nihon Nohyaku Japan Enter Assignment Agreement of Joint Patents
https://stocknessmonster.com/announcements/paa.asx-6A849472/
This complements endeavours to develop Monepantel as a lead therapy to treat cancers in
dogs and humans. PharmAust was recently granted patents covering “methods of use” for
Monepantel in cancer and non-cancer fields. The company is also progressing licensing
discussions with Elanco, which own the rights to Monepantel and has registered the drug for
use in animals. The recent agreement with NNC provides PharmAust with further scope to
independently commercialise its intellectual property .....

so that was 2017 I could go on mate but they also patented the use on SARs 2020.

for any more which there are plenty ,,research is the key..

The 2017 shareholder update "head to page 2"
https://stocknessmonster.com/announcements/paa.asx-6A822388/

best of luck with your investments NZT,, see history has a funny way of showing the truth....